Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K14/165

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/008642TREATMENT OF SARS-COV-2 INFECTION WITH A COMBINATION OF TARGETS
WO 13.01.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2021/068955 Applicant APEIRON BIOLOGICS AG Inventor WIRNSBERGER, Gerald
The invention provides a combination of a SARS-CoV-2 cellular entry receptor and a viral proliferation inhibitor for the treatment of a SARS-CoV-2 infection and combined pharmaceutical preparations and kit-in-parts.
2.WO/2022/008438STABILIZED CORONA VIRUS SPIKE PROTEIN FUSION PROTEINS
WO 13.01.2022
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/EP2021/068505 Applicant JANSSEN PHARMACEUTICALS, INC. Inventor LANGEDIJK, Johannes, Petrus, Maria
The present invention provides stabilized recombinant pre-fusion SARS CoV0-2 S proteins, nucleic acids molecules encoding the SARS CoV-2 S proteins and uses thereof.
3.WO/2022/011021USE OF CONSERVED PEPTIDE EPITOPES FROM SARS-COV-2 FOR THE DEVELOPMENT OF A BROAD COVID-19 VACCINE
WO 13.01.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/040700 Applicant ASCENDO BIOTECHNOLOGY, INC. Inventor LU, Yen-Ta
A vaccine for generation of immunity against SARS-CoV-2 infection includes an S2'-peptide of SARS-CoV-2 in a formulation that enhances immune responses, wherein the S2'-peptide includes the amino acid sequence selected from SEQ ID NO: 1-10. The formulation includes nanocomplexes encapsulating the S2'-peptide, or the formulation includes TREM-like transcript-1 (TREML1) extracellular domain (ECD) or a stalk peptide as an immune booster.
4.20220009972METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTION
US 13.01.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17246307 Applicant Jang Hyun HAN Inventor Jang Hyun HAN

The disclosure provides recombinant polypeptides for treating or preventing viral infection comprising an immunoglobulin Fc fragment and at least one viral receptor or fragment thereof. Also provided are RNA molecules, therapeutic compositions, and expression systems comprising such recombinant polypeptides, along with methods of preventing or treating a viral infection in a subject in need thereof, comprising administering such recombinant polypeptides to a subject or patient.

5.20220002699ACE2-Fc FUSION PROTEINS FOR SARS-COV-2 MITIGATION
US 06.01.2022
Int.Class C12N 9/48
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
48acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
Appl.No 17194282 Applicant PLANET BIOTECHNOLOGY, INC. Inventor Keith Lynn WYCOFF

The present disclosure relates to recombinant fusion proteins comprising an extracellular domain of the human angiotensin-converting enzyme 2 (ACE2), optionally having altered amino acid residues that result in increased binding affinity for the S1 spike protein of SARS-CoV-2, linked to a human immunoglobulin Fc region, that can extend the protein half-life (T1/2) and/or the duration of action as a decoy receptor, and compositions and methods of use of these fusion proteins.

6.WO/2022/000845RECOMBINANT PROTEIN VACCINE FOR PREVENTING SARS-COV-2 AND PREPARATION METHOD THEREFOR
WO 06.01.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2020/119701 Applicant JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION (PUBLIC HEALTH RESEARCH INSTITUTE OF JIANGSU PROVINCE) Inventor ZHU, Fengcai
A target amino acid sequence of a SARS-CoV-2 recombinant protein vaccine, a target gene sequence of the recombinant protein vaccine, a eukaryotic cell expression vector containing the target gene sequence, a cell expressing the target amino acid sequence, and the recombinant protein vaccine having the target amino acid sequence as an antigen. The recombinant protein vaccine can effectively induce a body to produce cellular immunity and humoral immunity, can be quickly prepared, and is suitable for the prevention of novel coronavirus.
7.WO/2022/003155A DNA PLASMID SARS-CORONAVIRUS-2/COVID-19 VACCINE
WO 06.01.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2021/068324 Applicant STATENS SERUM INSTITUT Inventor STRANDH, Charlotta Polacek
The present invention relates to DNA vaccine against SARS-Coronavirus-2 (SARS-CoV-2) infection. In particular, the present invention relates to a DNA vaccine encoding the SARS-Coronavirus-2 spike protein for use in prevention or treatment of viral infection in humans and/or animals. The DNA vaccine including the DNA construct has several features in its design that together provide a more safe and broad protection against SARS-CoV-2 strains in humans and animals, e.g. mink, ferrets, pigs and cats. The DNA construct encodes the SPIKE protein derived from the pandemic strain; Wuhan-Hu-1 (MN908947). The sequence is codon optimized for high expression in human and mammalian cells and the DNA construct is inserted in a selected DNA plasmid for eukaryotic in vivo and in vitro expression. The combination of the choice of SARS-CoV-2 SPIKE sequence, codon optimization, expression in the new generation eukaryotic expression plasmid with no antibiotic resistance marker (instead the RNA-OUT system is used for safety) and delivery to the very immunogenic skin, results in protection against SARS-CoV-2 infection and covid-19 disease.
8.WO/2021/262672SARS-COV-2 RBD CONSTRUCTS
WO 30.12.2021
Int.Class C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
Appl.No PCT/US2021/038411 Applicant THE SCRIPPS RESEARCH INSTITUTE Inventor SCHIEF, William
The present invention relates to glycan-masked and membrane-tethered SARS-CoV-2 RBD vaccine constructs and methods for making and administering the same. The present invention also encompasses a general vaccine platform for coronaviruses.
9.20210403537BINDING AGENTS TO PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN
US 30.12.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 17024392 Applicant ABclonal Science Inc Inventor Yang Xiang

Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.

10.113845577SARS-CoV-2特异性多肽及其应用
CN 28.12.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202111149547.4 Applicant 中国疾病预防控制中心病毒病预防控制所 Inventor 刘军
本发明公开了SARS‑CoV‑2特异性多肽及其应用,属于免疫检测领域。本发明提供了两条针对SARS‑CoV‑2特异性多肽,并且用相应多肽制备了多肽‑MHC四聚体,使用多肽‑MHC四聚体检测SARS‑CoV‑2感染康复者的T细胞,阳性率分别为3.63%、2.37%,明显高于阴性对照组0.061%、0.096%,有效地增加多肽‑MHC与特异性T细胞表面TCR的亲和力,可以作为T细胞评价的有效工具,该技术还可以用于特异性T细胞的分离与克隆,结合单细胞测序技术分离特异性TCR、作为T细胞激活试剂等。在对SARS‑CoV‑2感染或疫苗接种后人群的T细胞研究方面具有较高的应用价值。